ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,102.01
0.15%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Chemomab Therapeutics Ltd (CMMB) Share Price

CMMB Chemomab Therapeutics Ltd

1.20
0.05 (4.35%)
15 Jun 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Chemomab Therapeutics Ltd NASDAQ:CMMB NASDAQ Depository Receipt  ADS
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.05 4.35 1.20 1.03 1.24 1.20 1.0901 1.16 68,246 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics  -24.22M - N/A 
 Type  Size  Price  Time  Units 
 20 1,096 1.20 23:45:25 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore CMMB News
12/06/202421:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06/06/202412:00GLOBEChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
17/05/202412:00GLOBEChemomab Therapeutics to Participate in Upcoming Scientific Conferences
09/05/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
09/05/202412:00GLOBEChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
08/05/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08/05/202412:00GLOBEChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Period
Draw mode
Data Downloads for CMMB

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Chemomab Therapeutics Ltd Articles